MindWalk Holdings filed patent EP26187897.9, adding a computational layer to its foundational HYFT patent (EP3881326A1).1 The filing protects how MindWalk organizes biological meaning into a form reusable across its infrastructure and customer AI workflows.1
HYFT Technology encodes roughly 660 million biological patterns, universal fingerprints linking sequence, structure, and function.2 MindWalk also gave the first public demonstration of ReefIQ, its platform built on that representation layer.3
The bet: biological data is scattered across files, formats, and teams, and AI cannot reason usefully about drug discovery until that data is reconnected into one queryable structure.3 MindWalk's pitch to investors is that owning this representation layer, not any single model, is where durable advantage sits.3
MindWalk is not alone. NVIDIA BioNeMo, Boltz Lab, Owkin, Basecamp Research, and Edison Scientific are each racing to own the same layer underneath drug discovery. NVIDIA is anchoring lab-in-the-loop partnerships with Thermo Fisher and Eli Lilly, pulling equipment makers and pharma directly into AI-native discovery infrastructure.
Big pharma is restructuring around this shift rather than resisting it. Novo Nordisk closed its internal cell therapy unit and licensed the program to Cellular Intelligence instead of building it in-house.4 Novo Nordisk shares rallied nearly 25% over 30 days as the move signaled a pivot from vertical integration toward outsourced, AI-accelerated R&D.4
For traders, the signal is where value is concentrating: not in any single drug candidate, but in the data-representation layer sitting underneath discovery pipelines. NVIDIA's hardware-plus-partnership model gives it leverage on both the infrastructure and the pharma relationships. MindWalk's patent stack is a bet that the representation layer itself becomes a licensable asset, similar to how chip architecture licensing works. Novo Nordisk's outsourcing move suggests pharma majors increasingly prefer licensing AI-native platforms over rebuilding internal capability, a shift that favors the platform builders over incumbent R&D organizations if it holds across the sector.
